April 26 | 2021 2cureX styrelse och ledning nyttjar samtliga innehavda teckningsoptioner av serie TO1 för 6,04 MSEK Read more
April 24 | 2021 Correction of “Notice to attend the Annual General Meeting of 2cureX AB” issued on 23[rd] April 2021. Read more
April 24 | 2021 Korrektion till ”Kallelse till årsstämma i 2cureX AB” utfärdad den 23 april 2021. Read more
April 23 | 2021 Teckningskursen för utnyttjande av teckningsoptioner av serie TO1 i 2cureX AB har fastställts till 13,22 SEK och teckningsperioden inleds den 26 april 2021 Read more
April 23 | 2021 The exercise price for the warrants of series TO1 in 2cureX AB has been determined to SEK 13.22 and the subscription period starts April 26, 2021 Read more
March 1 | 2021 2cureX announces that the clinical trial of IndiTreat®-guided treatment of metastatic colorectal cancer has met the primary endpoint. Read more
January 28 | 2021 2cureX appoints Kenneth Graabek Johansen, an experienced business and financial executive, as new CFO. Read more
January 21 | 2021 Last patient treated in the world’s first interventional trial with 3D microtumors as guide for choice of cancer treatment. Read more
January 5 | 2021 2cureX appoints Fernando Andreu, an international Biotech executive, as new CEO Read more